SCHEMBL4928381

SCHEMBL4928381

O=C(Nc1ccccn1)c1ncsc1Nc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.52
RAB9A P51151 9/20 0.52
KMT2A Q03164 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
MEN1 O00255 4/20 0.52
PKM P14618 2/20 0.52
ADORA3 P0DMS8 1/20 0.52
PIM1 P11309 1/20 0.52
ADORA2A P29274 1/20 0.52
ADORA2B P29275 1/20 0.52
ADORA1 P30542 1/20 0.52
FLT3 P36888 1/20 0.52
PIM3 Q86V86 1/20 0.52
AURKB Q96GD4 1/20 0.52
GRM5 P41594 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.48
GAA P10253 1/20 0.48
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2826806 0.86 ATR (0.50) NPC1RAB9AKMT2AMEN1ADORA3
SCHEMBL2826317 0.80 NPC1 (0.59) NPC1RAB9APIM1
SCHEMBL2826686 0.78 KDM4E (0.54) PIM1KDM4EHDAC6
SCHEMBL4931447 0.75 NPC1 (0.52) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL14114415 0.74 CDK4 (0.47) FLT3CHRNB2CHRNA4HDAC1HDAC2
Hydrochloric Acid SCHEMBL4937569 0.74 CDK4 (0.46) FLT3CHRNB2CHRNA4HDAC1HDAC2
SCHEMBL2829644 0.73 NAMPT (0.51) NPC1RAB9ASMN1; SMN2ADORA3FLT3
SCHEMBL997866 0.71 RAB9A (0.89) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL29366822 0.71 RAB9A (0.89) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL7189774 0.70 RAB9A (0.86) NPC1RAB9AKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US claimed
EP-1781647-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP claimed
WO-2006008545-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-26 WO claimed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
EP-1781647-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006008545-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167309-A1 Pharmaceutical Compounds CCNO, CDK2, CDK1 NPC1 1595/4885RAB9A 3089/4885KMT2A 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.